Core Viewpoint - Plug Power (PLUG.US), a leading provider of hydrogen economy solutions, is set to announce its Q3 2025 earnings on November 10, with expectations of a wider loss and slight revenue decline compared to the previous year [1] Financial Performance Expectations - The market predicts a Q3 loss per share of $0.13, which represents a 48% increase in losses year-over-year [1] - Revenue is expected to be $170.02 million, reflecting a 2.1% decline compared to the same quarter last year [1] - Over the past 30 days, analysts have collectively raised their earnings expectations by 2%, indicating a positive adjustment trend [1] Business Segment Insights - Analysts forecast "net revenue (equipment, related infrastructure, and others)" to reach $98.03 million, down 8.5% year-over-year [1] - "Fuel cell systems and related infrastructure services net revenue" is expected to be $15.47 million, up 9.3% from the previous year [1] - "Power purchase agreement net revenue" is projected at $21.20 million, a 3.6% increase year-over-year [1] - "Net revenue (including fuel and related equipment delivered to customers)" is anticipated to be $32.53 million, reflecting a 9.2% growth compared to last year [1] Profitability Metrics - The expected gross profit for "fuel cell systems and related infrastructure services" is only $160,000, a significant decrease from $5.06 million in the same quarter last year [2]

Core Insights - CervoMed Inc. reported a quarterly loss of $0.84 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.68, and a decline from a loss of $0.55 per share a year ago, indicating a significant earnings surprise of -23.53% [1] - The company generated revenues of $0.32 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 69.24%, and a decrease from $1.94 million in the same quarter last year [2] - CervoMed Inc. shares have increased approximately 211.5% year-to-date, significantly outperforming the S&P 500's gain of 14.3% [3] Financial Performance - Over the last four quarters, CervoMed has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $0.9 million, and for the current fiscal year, it is -$2.58 on revenues of $5.12 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which CervoMed belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Core Viewpoint - PDF Solutions reported quarterly earnings of $0.25 per share, matching the Zacks Consensus Estimate, with revenues of $57.12 million, exceeding expectations by 0.91% [1][2] Financial Performance - The company achieved revenues of $57.12 million for the quarter ended September 2025, compared to $46.41 million a year ago, indicating a year-over-year growth of approximately 23% [2] - Over the last four quarters, PDF Solutions has surpassed consensus EPS estimates two times and topped revenue estimates twice [2] Stock Performance - PDF Solutions shares have increased by about 3.6% since the beginning of the year, while the S&P 500 has gained 15.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.30 on revenues of $60 million, and for the current fiscal year, it is $0.86 on revenues of $216.1 million [7] - The trend of estimate revisions for PDF Solutions was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Computer - Services industry, to which PDF Solutions belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests that the performance of stocks can be significantly influenced by the outlook for their respective industries [8]

Core Insights - Canada Goose reported a quarterly loss of $0.1 per share, missing the Zacks Consensus Estimate of a loss of $0.04, and compared to earnings of $0.04 per share a year ago, indicating an earnings surprise of -150.00% [1] - The company posted revenues of $197.96 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.55%, but showing a slight increase from year-ago revenues of $196.32 million [2] - Canada Goose shares have increased approximately 41.1% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for Canada Goose is mixed, with the current consensus EPS estimate for the coming quarter at $1.21 on revenues of $467.51 million, and $0.81 on revenues of $1.05 billion for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Apparel and Shoes industry, to which Canada Goose belongs, is currently in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Genesco, another company in the same industry, is expected to report quarterly earnings of $0.90 per share, reflecting a year-over-year change of +47.5% [9]

分组1 - CVRx reported a quarterly loss of $0.49 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.50, and an improvement from a loss of $0.57 per share a year ago, indicating an earnings surprise of +2.00% [1] - The company generated revenues of $14.69 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.33%, and showing an increase from $13.37 million in the same quarter last year [2] - CVRx has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has underperformed, losing about 21.2% since the beginning of the year, while the S&P 500 has gained 15.1%, raising questions about the stock's future performance [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $15.99 million, and for the current fiscal year, it is -$2.00 on revenues of $56.13 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 37% of over 250 Zacks industries, suggesting that the industry outlook is favorable and could positively impact stock performance [8]

Core Insights - Acadia Pharmaceuticals reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.20 per share a year ago, resulting in an earnings surprise of +85.71% [1] - The company achieved revenues of $278.63 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.84% and increasing from $250.4 million year-over-year [2] - Acadia's stock has increased by approximately 19.1% since the beginning of the year, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $284.97 million, and for the current fiscal year, it is $0.53 on revenues of $1.07 billion [7] - The estimate revisions trend for Acadia was favorable prior to the earnings release, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - X4 Pharmaceuticals reported a quarterly loss of $0.69 per share, better than the Zacks Consensus Estimate of a loss of $0.79, and a significant improvement from a loss of $5.41 per share a year ago, resulting in an earnings surprise of +12.66% [1] - The company generated revenues of $1.77 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 7.2%, but showing growth from $0.56 million in the same quarter last year [2] - X4 Pharmaceuticals shares have declined approximately 82% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for X4 Pharmaceuticals was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] - Current consensus EPS estimate for the next quarter is -$0.44 on revenues of $2.1 million, and for the current fiscal year, it is -$3.40 on revenues of $34.81 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which X4 Pharmaceuticals belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alvotech, another company in the same industry, is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year decline of 73.7%, with revenues projected at $128.22 million, up 24.5% from the previous year [9]

Core Insights - First Watch Restaurant Group, Inc. (FWRG) reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.08 per share, representing an earnings surprise of -37.50% [1] - The company posted revenues of $316.02 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.96%, compared to year-ago revenues of $251.61 million [2] - The stock has underperformed the market, losing about 14.8% since the beginning of the year, while the S&P 500 gained 16.5% [3] Earnings Performance - Over the last four quarters, the company has not surpassed consensus EPS estimates [2] - The current consensus EPS estimate for the coming quarter is $0.09 on revenues of $316.84 million, and $0.21 on revenues of $1.21 billion for the current fiscal year [7] Market Outlook - The company's earnings outlook and estimate revisions will be crucial for future stock performance [4] - The Zacks Rank for First Watch Restaurant Group is currently 3 (Hold), indicating expected performance in line with the market [6] - The Retail - Restaurants industry is currently in the bottom 14% of Zacks industries, which may impact stock performance [8]

Core Insights - InterDigital (IDCC) reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $1.79 per share, and up from $1.63 per share a year ago, representing an earnings surprise of +42.46% [1] - The company achieved revenues of $164.68 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.57% and increasing from $128.68 million year-over-year [2] - InterDigital's stock has increased approximately 97.6% year-to-date, significantly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of InterDigital's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $2.34 on revenues of $157.4 million, and for the current fiscal year, it is $14.71 on revenues of $815.8 million [7] Industry Context - The Wireless Equipment industry, to which InterDigital belongs, is currently ranked in the top 7% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Another company in the same industry, ViaSat (VSAT), is expected to report a quarterly loss of $0.11 per share, reflecting a year-over-year change of +89.7%, with revenues projected at $1.15 billion, up 2.4% from the previous year [9]

Core Insights - Cardinal Health reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.21 per share, and showing an increase from $1.88 per share a year ago, resulting in an earnings surprise of +15.38% [1] - The company achieved revenues of $64.01 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.39%, compared to $52.28 billion in the same quarter last year [2] - Cardinal shares have increased by approximately 39.1% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.23, with expected revenues of $62.1 billion, and for the current fiscal year, the EPS estimate is $9.45 on revenues of $249 billion [7] - The estimate revisions trend for Cardinal was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 21% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - McKesson, another company in the same industry, is expected to report quarterly earnings of $8.92 per share, reflecting a year-over-year change of +26.2%, with revenues anticipated to be $104.66 billion, up 11.8% from the previous year [9][10]